Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Echosens

Explore full profile

Develops diagnostic products for hepatology

Paris, FranceFounded 2001Biotech & Life Sciences
Valuation $100–250M Last recorded · 2015
Revenue $50–100M Latest reported FY
Headcount 100–500 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Echosens and the history behind them.

About Echosens

Echosens is a French company that specializes in non-invasive medical devices for the diagnosis and monitoring of chronic liver diseases. The company's flagship product, the FibroScan, is a non-invasive device that uses patented Vibration-Controlled Transient Elastography (VCTE) to measure liver stiffness and ultrasound attenuation for steatosis quantification. This technology provides a quantitative assessment of liver fibrosis and steatosis, which are key markers of liver health.

The company's business model is based on the sale of its FibroScan devices and related consumables to hospitals, clinics, and research institutions worldwide. Echosens also offers a range of services, including training, technical support, and clinical research support, to its customers. The company's target market includes hepatologists, gastroenterologists, and other healthcare professionals involved in the diagnosis and management of liver diseases.

Echosens has a global presence, with offices in Europe, North America, and Asia. The company's products are sold in over 100 countries, and it has a strong network of distributors and partners. Echosens is a well-established player in the liver disease diagnostics market, and its products are widely recognized for their accuracy, reliability, and ease of use.

Source: Dealroom company data

At a glance

Founded
2001
Headquarters
Paris, France
Sector
Biotech & Life Sciences
Power Law
Colt$25–100M revenue

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

Series B and later3 investors entered at this stage

  • PSL University
  • ESPCI Paris - PSL University
  • French National Centre for Scientific Research - CNRS
Employees mapped 384 incl. 3 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
22 countries with
team presence
🇫🇷 France50.3%
🇺🇸 United States28%
🇬🇧 United Kingdom4.7%
🇩🇪 Germany3%
🇮🇳 India2.4%
Top 5 of 22 shown
Web traffic by country
34K monthly visits
across markets
🇺🇸 United States35.3%
🇮🇳 India32.1%
🇮🇹 Italy8.2%
🇫🇷 France4.7%
🇬🇧 United Kingdom4.4%
Top 5 markets shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Echosens on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Echosens on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.